Clinical and pharmacokinetic properties of a transdermal nicotine patch.
We examined the pharmacokinetics of a transdermal nicotine patch and evaluated the usefulness of such a patch in a pilot smoking-cessation program. Use of the patch was associated with plasma nicotine concentrations that were comparable to smoking or to the use of other smoking-cessation devices. However, these plasma concentrations were maintained for 24 hours, and the patch appeared to be suitable for use once a day. Its use in a 6-week placebo-controlled double-blind study resulted in a significant degree of smoking cessation or in reduction of smoking activity. The findings suggest that it may be valuable to extend investigations to a larger population and that transdermal nicotine may have a useful role in smoking-cessation therapy.
Mulligan
S C
SC
Elan Corporation, Athlone, Ireland.
Masterson
J G
JG
Devane
J G
JG
Kelly
J G
JG
D000279:Administration, Cutaneous; D000328:Adult; D006801:Humans; D008297:Male; D009538:Nicotine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D010865:Pilot Projects; D000074606:Smoking Prevention; D014029:Tobacco Use Disorder / Q000378:metabolism / Q000523:psychology*
D009538:Nicotine